Non Animal Testing Database

SARS-CoV-2 vaccination responses in patients with immune diseases

Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
The authors analysed the vaccination responses in 84 patients with immune-mediated inflammatory diseases (IMIDs) and 182 healthy adults (controls) vaccinated with the BNT162b2 mRNA SARS-CoV-2 vaccine (BioNTech/Pfizer). 99.5% of controls but only 90.5% of patients with IMID developed neutralising antibody activity. Furthermore, the overall immune responses were delayed in patients with IMID. A lower incidence of side effects was also detected in these patients.
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
Georg Schett
Added on: 05-12-2021
Back to Top
English German

Warning: Internet Explorer

The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.

Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!